Chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of pancreatic cancer

Pancreatic cancer is one of the leading causes of cancer-related mortality in both developed and developing coun-tries.The incidence of pancreatic cancer in China accounts for about a quater of the global incidence,and the epidemiological characteristics and therapeutic strategies differ due to social,economic,cultural,environmental,and public health factors.Non-domestic guidelines do not reflect the clinicopathologic characteristics and treat-ment patterns of Chinese patients.Thus,in 2018,the Chinese Society of Clinical Oncology(CSCO)organized a panel of senior experts from all sub-specialties within the field of pancreatic oncology to compile the Chinese guidelines for the diagnosis and treatment of pancreatic cancer.The guidelines were made based on both the Western and Eastern clinical evidence and updated every one or two years.The experts made consensus judg-ments and classified evidence-based recommendations into various grades according to the regional differences,the accessibility of diagnostic and treatment resources,and health economic indexes in China.Here we present the latest version of the guidelines,which covers the diagnosis,treatment,and follow-up of pancreatic cancer.The guidelines might standardize the diagnosis and treatment of pancreatic cancer in China and will encourage oncologists to design and conduct more clinical trials about pancreatic cancer.

Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers

Background:Biliary tract carcinoma(BTC)is relatively rare and comprises a spectrum of invasive tumors arising from the biliary tree.The prognosis is extremely poor.The incidence of BTC is relatively high in Asian countries,and a high number of cases are diagnosed annually in China owing to the large population.Therefore,it is necessary to clarify the epidemiology and high-risk factors for BTC in China.The signs associated with BTC are complex,often require collaborative treatment from surgeons,endoscopists,oncologists,and radiation therapists.Thus,it is necessary to develop a comprehensive Chinese guideline for BTC.Methods:This clinical practice guideline(CPG)was developed following the process recommended by the World Health Organization.The Grading of Recommendations Assessment,Development,and Evaluation approach was used to assess the certainty of evidence and make recommendations.The full CPG report was reviewed by external guideline methodologists and clinicians with no direct involvement in the development of this CPG.Two guideline reporting checklists have been adhered to:Appraisal of Guidelines for Research and Evaluation(AGREE)and Reporting Items for practice Guidelines in Healthcare(RIGHT).Results:The guideline development group,which comprised 85 multidisciplinary clinical experts across China.After a controversies conference,17 clinical questions concerning the prevention,diagnosis,and treatment of BTC were proposed.Additionally,detailed descriptions of the surgical principles,perioperative management,chemotherapy,immunotherapy,targeted therapy,radiotherapy,and endoscopic management were proposed.Conclusions:The guideline development group created a comprehensive Chinese guideline for the diagnosis and treatment of BTC,covering various aspects of epidemiology,diagnosis,and treatment.The 17 clinical questions have important reference value for the management of BTC.